UNSPSC 51201574: Palivizumab

A humanized monoclonal antibody (IgG1? ) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).

UNSPSC 51201574 Palivizumab is a Commodity code that nominally identifies a respiratory syncytial virus (RSV) monoclonal antibody pharmaceutical product, but the recent state and local opportunities tagged under this code show no alignment with pharmaceutical procurement. The three most recent posted solicitations—a District Attorney's Office dog from Washington County, Oregon; athletic training services for fire and police departments from the City of Tucson; and medical aid supplies from the City of Tampa Fire Rescue—represent unrelated work in public safety staffing, occupational health services, and emergency medical consumables respectively. The code shows little relevant recent activity for its stated pharmaceutical scope.

No state and local government procurement activity for palivizumab or related RSV immunoprophylaxis products appears in the recent-opportunities block. The mismag between the code's pharmaceutical definition and the work actually being solicited under it suggests either a data-entry error in the source system or a systematic miscoding issue. Firms with palivizumab supply or distribution capabilities should not rely on this UNSPSC code for state and local contract discovery; direct outreach to state health departments, Medicaid programs, and pediatric hospital networks remains the appropriate channel for this product category.